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Background: The genotype information carried by Genome-wide association studies (GWAS) seems to have the
potential to explain more of the ‘missing heritability’ of complex human phenotypes, given improved statistical
approaches. Several lines of evidence support the involvement of microRNA (miRNA) and other non-coding RNA in
complex human traits and diseases.
We employed a novel, genetic annotation-informed enrichment method for GWAS that captures more polygenic
effects than standard GWAS analysis, to investigate if miRNA-tagging Single Nucleotide Polymorphisms (SNPs) are
enriched of associations with 15 complex human phenotypes. We then leveraged the enrichment using a conditional
False Discovery Rate (condFDR) approach to assess any improvement in the detection of individual miRNA SNPs
associated with the disorders.
Results: We found SNPs tagging miRNA transcription regions to be significantly enriched of associations with 10 of 15
phenotypes. The enrichment remained significant after controlling for affiliation to other genomic categories, and was
confirmed by replication. Albeit only nominally significant, enrichment was found also in miRNA binding sites for 10
phenotypes out of 15. Leveraging the enrichment in the condFDR framework, we observed a 2-4-fold increase in
discovery of SNPs tagging miRNA regions.
Conclusions: Our results suggest that miRNAs play an important role in the polygenic architecture of complex human
disorders and traits, and therefore that miRNAs are a genomic category that can and should be used to improve gene
discovery.
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Genome-wide association studies (GWAS) have identified
thousands of single nucleotide polymorphisms (SNPs) as-
sociated with complex human traits and diseases in the
last years. However, these variants explain only a small
proportion of the estimated heritability. The failure to
explain a substantial proportion of the heritability of
complex phenotypes is often described as the "missing
heritability" problem [1,2]. Some of the missing herit-
ability may lie with very rare variants of large effect yet* Correspondence: srdjan.djurovic@medisin.uio.no
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unless otherwise stated.to be detected [3] but heritable complex diseases and
traits are also widely believed to have an underlying
polygenic architecture [4,5] characterized by a large
number of not so rare variants with effects too small to
be captured by standard statistical approaches.
Recent studies have shown that the genotype informa-
tion in GWASs can be used to explain more of the herit-
ability of common complex traits than revealed by
standard analytical methods [6,7]. New statistical ap-
proaches have been developed to improve SNP discovery
and uncover more polygenic effects without increasing
the sample size [7-9]. These new methods exploit the
notion that some SNP categories are more likely to have
a true effect than others. Schork et al. [7] showed that
SNPs in some genomic regions (e.g. 5’UTR, 3’UTR,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions as compared to the baseline. It is a plausible as-
sumption that other genomic categories too could be
enriched of such associations with complex human
phenotypes.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs (~22 nucleotides long) that regulate gene expres-
sion by inhibiting protein translation or by degrading the
mRNA transcript [10,11]. A single miRNA may regulate
hundreds of functional targets within one cell type simul-
taneously, providing the cell with an intricate mechanism
for fine-tuning the regulation of gene expression. Over
1,500 human miRNAs are reported in miRBase version 19
(http://mirbase.org). Like protein-coding genes, miRNAs
are transcribed mainly by polymerase II as long primary
transcripts (pri-miRNAs) in the nucleus. However, in con-
trast to protein-coding genes, they are subsequently
cleaved to produce stem loop structured precursor mole-
cules (pre-miRNAs) by the nuclear RNase III enzyme
Drosha along with other factors [12]. The pre-miRNAs
are then exported to the cytoplasm by exportin-5 [12],
where the RNase III enzyme Dicer further processes them
into mature, short miRNAs that are subsequently incorpo-
rated into the RNA-induced silencing complex.
MiRNAs are able to impact a variety of cellular path-
ways and functions. Several studies have shown that
miRNAs are critical to development, apoptosis, cell pro-
liferation, immunity, and patterning of the nervous
system [13,14]. Deregulation of miRNAs leads to a var-
iety of human diseases [15]. Several studies suggest that
around 30% to 50% of all human genes are regulated by
miRNAs [11,16]. Moreover, as has emerged from GWAS
data [17], more than 90% of disease-associated SNPs are
located in non-coding regions of the genome, for ex-
ample in promoter regions, enhancers, silencers, or even
in non-coding RNA genes. It is therefore reasonable to
assume that a number of such non-coding variants may
affect miRNA transcription or be involved in the disrup-
tion or the creation of miRNA binding sites. Variants in
miRNA primary transcripts can affect the expression of
miRNAs by altering miRNA processing inside the nu-
cleus. Variants in mature miRNAs or miRNA binding
sites can generate gain and loss of function, leading to
alterations of the genetic pathways in which those miR-
NAs are involved [17]. We therefore expect SNPs
located in miRNA transcription regions and miRNA
binding sites to be more likely to show significant associ-
ations with complex human phenotypes compared to
baseline SNPs (“enrichment of miRNA vs. baseline
SNPs”).
In order to test this hypothesis, we applied the
genomic annotation-informed enrichment method first
employed by Schork et al. [7]. We first calculated the
relative enrichment of miRNA tagging SNPs using thesummary statistics GWAS data of 15 complex human
phenotypes. We then leveraged the enrichment in a con-
ditional False Discovery Rate (condFDR) framework to
assess the improvement in the detection of individual
miRNA-related SNPs associated with these phenotypes.
We found that SNPs tagging miRNA sites and binding
sites were more likely to be associated with the pheno-
types compared to baseline SNPs (i.e. intergenic SNPs),
though less compared for instance to 5’UTR SNPs. A
similar enrichment pattern was shown across the major-
ity of human phenotypes investigated.
Methods
Samples
Genome-wide association study (GWAS) summary sta-
tistics data from 15 phenotypes including i) brain-related
disorders and traits: bipolar disorder (BD) [18], schizo-
phrenia (SCZ) [19], smoking behaviour as measured by
cigarettes per day (CPD) [20], ii) cardiovascular risk fac-
tors (including metabolic diseases): systolic blood pressure
(SBP) [21], plasma lipids (triglycerides, TG, high density
lipoprotein, HDL, low density lipoprotein, LDL) [22], type
2 diabetes [23] iii) immune-mediated diseases: multiple
sclerosis (MS) [24],Crohn’s disease (CD) [25], ulcerative
colitis (UC) [26], and iv) anthropomorphic measures: body
mass index (BMI) [27], height [6] waist to hip ratio
(WHR) [28], and v) prostate cancer [29] were included in
the present study. The summary statistics (p-values or
z-scores) were obtained from public access websites or
published supplementary material. A description of the
underlying GWAS data is presented with Additional file 1.
In total, these studies comprised approximately 1.3 mil-
lion phenotypic observations, but considerable sample
overlap makes the number of unique individuals lower.
The p-values from the respective GWAS meta-analyses,
derived according to best practices, underwent no
further processing with the exception of a correction for
inflation. The baseline statistic for the control of inflation was
computed from intergenic SNPs [7]. Also, SNPs with
reference (rs) numbers that did not map onto the 1000
genomes project (1KGP) reference panel were excluded.
miRNAs transcription regions (miRNA)
The human miRNA data was downloaded from miRBase
(www.mirbase.org) version 19, which includes published
miRNA sequences and annotations. The human dataset
of miRBase version 19 has 1,595 primary transcripts
with genomic coordinates, name and accession number
of each miRNA [30]. Before converting the miRBase
human data set to a suitable file format, the primary
transcript coordinate intervals of the miRNAs were
extended by ten kilobases in both directions in order to
include SNPs in the regulatory regions of the miRNAs
themselves [31].
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miRNA validated targets were downloaded from miRe-
cords (http://www.hsls.pitt.edu/obrc/index.php?page=URL
1237998207), version 4, last updated April 2013. MiRe-
cords consists of validated and predicted miRNA targets
[32]. The validated targets component is a large, high-
quality database of experimentally validated miRNA tar-
gets resulting from manual curation of literature. We ob-
tained 1,214 human miRNA targets from miRecords that
were used to create the miRNA target regions annotation
category (see Positional annotation categories below).
Positional annotation categories
Bi-allelic SNP genotypes from the European reference
sample provided by the November 2010 release of Phase
1 of the 1KGP were obtained in pre-processed form from
http://www.sph.umich.edu/csg/abecasis/MACH/download/.
Basic quality control functionalities of Plink version 1.07
[33] (32) were applied: SNPs with a minor allele frequency
of less than 1%, missing in more than 5% of individuals
and/or violating Hardy-Weinberg equilibrium (p < 1×10−6)
were excluded from the reference panel; individuals miss-
ing more than 10% of the genotypes were excluded. All
remaining 1KGP SNPs were assigned single, mutually
exclusive genic annotation categories based on their
genomic position (hg19). Genic annotation categories
were: 1) miRNA transcription regions (miRNA); 2)
miRNA binding sites (miRNA-BS); 3) 3’-untranslated
region (3’UTR); 4) intron; 5) exon; 6) 5’-untranslated
region (5’UTR); 7) Enhancer; 8) Silencer; 9) transcrip-
tion factor binding site (TFBS); 10) non-coding RNA
(NCRNA); and 11) intergenic.
Linkage disequilibrium (LD) weighted SNP category scoring
The use of tag SNPs in GWAS limits the discovery of
functional variants within a ”tagged” linkage block, po-
tentially overseeing the effect of other variants in only
partial linkage disequilibrium (LD) with their tag SNP.
In the current study the LD between SNPs was incorpo-
rated as part of a strategy devised to obtain a stronger
and more consistent differentiation of enrichment among
several annotation categories [7]. In our enrichment ana-
lysis an LD-weighted scoring algorithm allows the quanti-
fication of the properties of multi-locus LD structure
implicitly captured by each tag SNP. The resulting LD-
informed categories are leveraged as strata for the subse-
quent analysis [7-9].
For each GWAS tag SNP a pairwise correlation coeffi-
cient approximation to LD (r2) was calculated for all
1KGP SNPs within a 1,000,000 base pairs (1Mb) distance
that passed quality control (see above). All r2 values < 0.2
were set to 0 and each SNP was assigned an r2 value of
1.0 with itself. LD-weighted annotation scores for each
category were computed as the sum of LD r2 betweenthe tag SNP and all 1KGP SNPs in that category (±10
kilobases in the case of miRNA, see above).
Given SNPi, its LD-weighted annotation score for an
annotation category was computed as:
LD infoi ¼ Σj δj  rij2ð Þ;
where rij2 is the LD r-squared between SNPi and SNPj
and δj takes values of 1 or 0 depending on whether the
1KGP SNPj belongs to the annotation category or not.
Each tag SNP was then “LD”-assigned to that annotation
category if its LD-weighted annotation score was greater
than or equal to 1.
Intergenic SNPs
Intergenic SNPs were defined as having LD-weighted an-
notations scores for each of the other categories equal to
zero and being in LD with no SNPs in the 1KGP refer-
ence panel located within 100,000 base pairs of a protein
coding gene, within a non-coding RNA, within a tran-
scription factor binding site or within a miRNA binding
site. Those singled out in this way are expected to form
a collection of non-genic SNPs not belonging to any
(annotated) functional elements within the genome (in-
cluding through LD) and therefore represent a collection
of likely null associations [7].
Intergenic Inflation Control
The empirical null distribution in GWAS is affected by
global variance inflation due to population stratification
and cryptic relatedness [15] and deflation due to the
over-correction caused by the application of standard
genomic control methods to polygenic traits [16]. We
applied a control method leveraging only intergenic
SNPs that are likely depleted of true associations. The
following procedure was carried out for each phenotype:
after conversion of p-values into z-scores, the genomic
inflation factor [15], λGC, was estimated as the median
squared z-score across intergenic SNPs divided by the
expected median of a chi-square distribution with one
degree of freedom (the .95 quantile was used for CPD in
place of the median). We used intergenic SNPs to esti-
mate inflation because their relative depletion of associa-
tions suggests they provide a robust estimate of true null
SNPs that is uncontaminated by polygenic effects. Using
annotation categories in this fashion is important given
concerns posed by recent GWAS [8] about the over-
correction of test statistics using standard genomic
control.
Quantile-Quantile (Q-Q) Plots and Enrichment
Q-Q plots are used to compare two distributions. The
Q-Q plots reported here show -log10 nominal p-values
plotted against -log10 empirical p-values for different
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Leftward deflections of the observed distribution from
the projected null line reflect increased tail probabilities
in the distribution of the test statistic and consequently
larger proportions of low p-values with respect to the
one expected by chance. An increased deflection from
the null line in the Q-Q plots of summary statistics con-
ditioned on a genomic category is referred to here as
“enrichment” of that genomic category [7].
Binomial proportion test
In order to assess the statistical significance of the en-
richment, the SNPs in the summary statistics data from
the GWAS studies were first pruned of LD redundancy.
This was done by randomly selecting ten different sets
of representatives from sliding 1Mb LD (r2 > 0.2) win-
dows. The proportions of SNPs in all given annotation
categories were subsequently compared to the proportion
of intergenic SNPs in the top decile using a binomial pro-
portion test [34]. A p-value was finally computed from the
median of the binomial proportion test statistics over the
ten replicas.
Enrichment estimates
As explained in detail by Schork et al. [7], an overall es-
timate of the categorical enrichment graphically illus-
trated in the Q-Q plots is the sample mean of z2 - 1,
where the sample mean is taken over all the SNPs z-
scores in the given category. Assuming the z-score dis-
tribution in a given category to be a mixture of a stand-
ard normal null distribution and a non-null distribution
also symmetric around zero, the sample mean z2 for the
SNPs over that category provides an estimate of the vari-
ance due to all null and non-null SNPs in that category.
By subtracting one, we obtain a conservative estimate of
the variance in effect sizes attributable to non-null SNPs
alone. The miRNA enrichment estimates for all pheno-
types were computed and joined with the estimates
computed by Schork et al. [7] for other genic categories.
All estimates where then normalized by the largest value
per phenotype.
Regression
Another way of testing whether a covariate of interest, e.g.
an LD-informed genic annotation score, predicts associ-
ation with a given phenotype is to regress a proxy for the
association against the covariate. We regress here the
logarithm of the squared association z-scores (as we are
not interested in the direction of effect) against the LD-
informed genic annotations scores. The inclusion of affili-
ation scores for the most relevant genic categories in the
regression accounts for possible latent mediation effects.
Different genic categories can encompass LD-blocks of
very different sizes and therefore have rather differentaffiliation scores distributions. These could bias the en-
richment significance measured through the binomial
proportion test. An estimate of the SNPs total LD is in-
cluded in the regression to account for this potential
bias. The total LD of a SNP (TotLD) is measured as the
sum of pairwise LD r2 greater or equal than 0.2 between
a SNP and all 1KGP SNPs within 1,000,000 base pairs
from it.
Conditional False Discovery Rate (condFDR)
The enrichment expressed in the Q-Q plots can be
directly interpreted in terms of the Bayesian False Dis-
covery Rate (FDR) [35]. Specifically, for a given p-value
cutoff, the FDR is defined as
FDR pð Þ ¼ π0F0 pð Þ =F pð Þ;
where π0 is the proportion of null SNPs, F0 is the null
cumulative distribution function (cdf ), and F is the cdf
of all SNPs, both null and non-null. Under the null hy-
pothesis, F0(p) = p is the cdf of the uniform distribution
on the unit interval [0,1], so
FDR pð Þ ¼ π0p=F pð Þ:
F is estimated by the empirical cdf q =Np/N, where Np
is the number of SNPs with p-values less than or equal
to p, and N is the total number of SNPs. If π0 is close to
one, as is likely true for most GWASs, a reasonable con-
servative estimate of FDR is p/q. The negative decadic
logarithm of this FDR estimate is log10(q) - log10(p) which
coincides with the aforementioned deflection from the
null line.
The conditional False Discovery Rate (condFDR) is con-
servatively estimated as FDR(p | x) = p / F(p | x), where x is
the value of a given annotation X, and F(p | x) is the cdf of
p conditional on the annotation X = x. If SNPs are enriched
for associations according to levels of X, then F(p | x) >
F(p) for a given p and hence FDR(p | x) < FDR(p).
Replication
In order to test the specificity of the condFDR method,
we looked at the replication rate across independent
samples. Both the data and the procedure used to com-
pute the conditional rate of replication closely follow the
ones used by Schork et al. [7]. Initially, the z-scores of
each of the eight original sub-studies contributing to the
CD meta-analysis were independently adjusted using
intergenic inflation control. The eight sub-studies were
then subdivided into two groups of four in 8
4
 
= 70
ways, the first group, Dk, k = 1,…,70, serving as discov-
ery group, the second, Rk, k = 1,…,70, as replication
group. Average discovery and replication z-scores were
computed for all SNPs and all 70 subdivisions and
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studies in the group.
The average z-scores were converted to p-values
using the standard normal cumulative distribution
function Φ. Two-tailed discovery p-values were calcu-
lated as pD = 1-Φ(|ZD|) +Φ(−|ZD|) = 2*Φ(−|ZD|), one-
tailed replication p-values preserving the signs of the
discovery z-scores were calculated as pR =Φ(sgn(ZD) * ZR).
Separate cumulative replication rates were calculated
for each category (miRNA, Intergenic and All SNPs)
over each of 1,000 equally-spaced bins spanning the
range of negative log10(p-values) observed in the discov-
ery group and for each of the 70 subdivisions. Every cu-
mulative replication rate was calculated as the fraction
of SNPs with a discovery negative log10(p-value) greater
than the lower bound of the bin, that had a replication
p-value smaller than 0.05. Average cumulative replica-
tion rates were subsequently computed across the 70
subdivisions. The True Discovery Rate - TDR (1-FDR)
computed from the GWAS summary statistics can be
thought of as the replication rate in an independent
sample as the size of the replication sample goes to
infinity. In practice, both the TDR and the cumulative
replication rates are estimated with some error so that
the former will not perfectly predict the latter. A sub-
stantial correspondence between the two is nonetheless
to be expected for reasonable discovery and replication
sample sizes.
Results
Enrichment of miRNA tagging SNPs
The stratified Q-Q plots for height, LDL, CD and SCZ
plotted with confidence intervals show a general enrich-
ment pattern for miRNA (Figure 1) and miRNA-BS
(Additional file 1) categories, illustrated by an early
departure from the null line which is consistent with a
greater proportion of true associations for a given
p-value threshold. The deviation from the null line is
more pronounced for miRNA and miRNA-BS–related
SNPs than for all SNPs together or intergenic SNPs. In
fact, miRNA and miRNA-BS seem largely as enriched as
3'UTR, among the annotation categories shown by
Schork et al. [7] to have the largest abundance of associ-
ations. For example, the proportion of SNPs reaching a
significance level of p < 10−4 is roughly ten times greater
in the miRNA category than in the intergenic category.
The same pattern is present in most of the other pheno-
types, exception being CPD (Additional file 1). The
parallel shapes of these curves are likely caused by the
significant, though not complete, correlation among
the categories due to the non-exclusive nature of the
annotation scoring. Although the enrichment pattern of
miRNAs is persistent through most of the phenotypes
in the study, the shape of the curves varies across them.This is consistent with different levels of polygenicity
in different phenotypes but may also be due to different
degrees of involvement of miRNA in the etiology of dif-
ferent phenotypes.
Significance of enrichment
We computed significance values for the enrichment of
each annotation category relative to intergenic SNPs,
using the binomial proportion test (Table 1). The enrich-
ment for miRNAs is nominally significant in all pheno-
types except CPD and PrCa, and, after correcting for
multiple testing of 15 phenotypes, only BD, MS, T2D
become unconvincing; miRNA-BSs are significantly
enriched in BD, BMI, CD, HDL, Height, LDL, SBP, TG,
UC, and WHR (Additional file 1), but the effect is less
evident across several of them and only BMI, Height,
and LDL remain significant after correcting for
multiple testing of 15 phenotypes. The significance
of the enrichment in Height, LDL, CD and SCZ
using LD-pruned SNPs is also illustrated with the
visual aid of confidence intervals in Figure 1 and Additional
file 1.
Due to the considerable differences among the studies
the enrichment p-values may not be directly comparable
to one another but they remain nonetheless a reliable in-
dicator of significance.
miRNA enrichment in relationship to other genomic
regions
It was previously shown across several traits that the
summary statistics resulting from SNPs in LD with
5'UTR and 3'UTR show the largest abundance of associ-
ations, while those from SNPs in LD with intergenic re-
gions show a depletion of associations relative to the
baseline [6,7,36]. We compared the relative pattern of
enrichment of miRNA, 5’UTR and 3'UTR in stratified
Q-Q plots for height, LDL, CD and SCZ (Additional
file 1). In all four phenotypes miRNA-tagging SNPs show
similar levels of enrichment as those tagging 5’UTR and
3’UTR. In order to rule out the possibility that the correl-
ation with other genic categories might drive the
enrichment of miRNA, following Schork et al.’s procedure
[7], we regressed the summary statistics z2 against the
LD-informed annotation values for miRNA, miRNA-BS,
3’UTR, 5’UTR, Exon, Intron as well as Intergenic and
total LD. The regression showed a significant residual
independent effect of miRNA on the z2 (Additional file 1).Quantification of Enrichment
The mean of z2-1 per SNP annotation category was used
to get a quantitative measure of the enrichment of that
category for association with each phenotype. The
enrichment scores, normalized by the maximum value
Table 1 Significance of miRNA enrichment
Phenotype BPT p-value
BD 2.4e-02§
BMI 1.0e-12*
CD 1.9e-06*
CPD 6.3e-01
HDL 2.2e-20*
Height 3.9e-90*
LDL 2.6e-17*
MS 3.3e-03§
PrCa 1.1e-01
SBP 9.8e-08*
SCZ 4.1e-07*
T2D 9.8e-03§
TG 1.5e-16*
UC 3.2e-06*
WHR 5.8e-06*
Significance of miRNA enrichment in 15 phenotypes. Reported are the
binomial proportion test (BPT) p-values for miRNA target regions compared
with intergenic SNPs for all phenotypes. CPD and PrCa do not reach nominal
statistical significance; BD, MS, and T2D would not pass strict multiple testing
criteria for 15 phenotypes – BD, Bipolar Disorder; BMI, Body Mass Index; CD,
Crohn's disease; CPD, Cigarettes per Day; HDL, High density lipoprotein; LDL,
Low density lipoprotein; MS, multiple sclerosis; PrCa, prostate cancer; SBP,
systolic blood pressure; SCZ, Schizophrenia; T2D, Type 2 Diabetes; TG,
triglycerides; UC, Ulcerative Colitis; WHR, Waist to Hip Ratio. § Nominally
significant (not significant after controlling for multiple testing); * Significant.
Figure 1 miRNA stratified Q-Q plots for Height, Low Density Lipoprotein (LDL), Crohn’s Disease (CD) and Schizophrenia (SCZ) using Linkage-
Disequilibrium (LD)-weighted annotation scores. Shown are Q-Q plots for miRNA SNPs compared to those for all SNPs and intergenic SNPs,
a collection of likely null SNPs. The confidence intervals were obtained by sampling ten independent sets of SNP representatives from all
LD-blocks (r2 > 0.2) and computing means and confidence intervals for one thousand bins of nominal p-value.
Goulart et al. BMC Genomics  (2015) 16:304 Page 6 of 10across categories within each phenotype, are presented
in Figure 2 and Additional file 1. The 5′UTR annotation
category shows the highest mean z2-1 in almost all phe-
notypes but is followed, often closely, by miRNA or
miRNA-BS (Additional file 1).
Replication rate and condFDR
To further address the possibility that the observed pat-
tern of differential enrichment results from spurious (i.e.,
non-generalizable) associations due to category-specific
confounding effects or statistical modeling errors, we also
studied the empirical replication rate across independent
sub-studies of Crohn’s Disease (CD) for which eight sub-
studies summary statistics were readily available. Figure 3
shows the empirical cumulative replication rate plots as a
function of nominal p-value for miRNA, intergenic and all
SNPs. As can be seen, an order of magnitude lower p-
values are necessary for intergenic SNPs compared to
miRNA SNPs s to achieve a wide range of replication rates
(0.2 – 0.8). Or, seen from a different perspective, miRNA
SNPs replicate at consistently higher rates, e.g. up to five
times higher than intergenic SNPs for p-values lower than
0.01. This encouraged us to examine the conditional false
discovery rates to assess the improvement achievable in the
detection of miRNA-related loci. The condFDR method
improves the discovery of SNPs in the miRNA category
across all phenotypes, with an average ~ three-fold increase
Figure 2 Categorical Enrichment for Height, Low Density Lipoprotein (LDL), Crohn’s Disease (CD) and Schizophrenia (SCZ). The relative pattern
of enrichment of LD-weighted genic annotation categories, as measured by the mean (z-score2 - 1) normalized by the highest value across
categories within each phenotype after intergenic inflation control, remains consistent. Results for all phenotypes are shown in Additional file 1.
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companied by the same or a better replication rate, the
method provides increased power.
Discussion
The main finding of the current study is that SNPs in
miRNA-related regions show a significant and persistent
pattern of association enrichment in a variety of com-
plex human phenotypes. This supports the thesis that
miRNAs play an important role in the etiology of these
phenotypes, and further illustrates the polygenic archi-
tecture of complex human phenotypes.
The traditional statistical approach to GWASs has
thus far only explained a small proportion of the ob-
served heritability of complex human traits and disor-
ders. However, previous studies have suggested that
higher proportions of polygenic effects are to some ex-
tent actually detectable in existing GWAS data [37]. The
statistical framework adopted here is based on the rea-
sonable assumption that SNPs in different genomic re-
gions are not equally likely to affect the phenotypes.
Rather, as has been shown before, SNPs within certain
functional regions of the genome [7] or SNPs with pos-
sible pleiotropic effects are more prone to show
association.
A large share of miRNA transcription regions and, by
their very nature, all miRNA target regions are clustered
in or around genes. This exposes the SNPs held within
such regions to correlation with SNPs in other geniccategories (e.g., 3’UTR, 5’UTR, exons, introns). This cor-
relation is further exasperated by the LD-weighting pro-
cedure applied to account for indirect effects. And
indeed, controlling for this correlation does reduce the
significance of miRNA enrichment, which however for
the most part holds, suggesting it contains a residual
pure miRNA component [38]. Further, the replication
analysis shows clearly that SNPs tagging miRNA are
more likely to be replicated, which is a very compelling
argument in favour of true discoveries. The replication
results emboldened us to use the LD-weighted miRNA
annotations, combined with an established method for
computing conditional False Discovery Rates, to improve
the discovery of SNPs in GWAS.
The statistical framework employed here has else-
where been exploited to identify specific SNP associa-
tions, which are otherwise undetected by traditional
GWAS analyses [8,9]. The current findings suggest that
leveraging information about miRNA affiliation leads to
an increased number of identified gene loci, as shown
for all phenotypes in Table 2. The increase is not due
merely to an effective lowering of the significance
threshold, since the condFDR method also re-ranks the
SNPs, privileging those with higher prior likelihood of
association. Indeed, for Crohn’s disease (Figure 3) we
show that miRNA SNPs identified with the condFDR
method have a higher probability of replicating in inde-
pendent samples (replication rate). This is not the case
for discoveries attained by lowering the threshold.
Table 2 Number of significant miRNA genomic loci
Phenotype condFDR FDR p-value
(<0.01) (<0.01) (Bonferroni)
BD 8 2 0
BMI 7 5 3
CD 55 34 16
CPD 1 0 0
HDL 52 38 18
Height 189 123 51
LDL 62 37 19
MS 51 42 25
PrCa 16 12 6
SBP 12 6 2
SCZ 29 14 6
T2D 1 1 1
TG 84 43 20
UC 54 36 18
WHR 4 3 0
Comparative table showing number of identified genomic loci with conditional
false discovery rate (condFDR < 0.01) compared with false discovery rate
(FDR < 0.01) and standard p-value (Bonferroni correction p < 5×10−8). We
show that the condFDR method improves the discovery of miRNA SNPs
across the 15 phenotypes. The numbers reported here are after pruning SNPs
for LD at a threshold of r2 ≤ 0.2. BD, Bipolar Disorder; BMI, Body Mass Index;
CD, Crohn's disease; CPD, Cigarettes per Day; HDL, High density lipoprotein;
LDL, Low density lipoprotein; MS, multiple sclerosis; PrCa, prostate cancer;
SBP, systolic blood pressure; SCZ, Schizophrenia; T2D, Type 2 Diabetes; TG,
triglycerides; UC, Ulcerative Colitis; WHR, Waist to Hip Ratio.
Figure 3 Independent study replication confirms enrichment in
Crohn’s Disease. Shown are plots of (A) stratified true discovery rate
(TDR) and (B) cumulative replication rate as functions of the
negative decadic logarithm of the p-value. The p-value in the
cumulative replication rate plot refers to the p-value in the discovery
sample. Replication is intended as achieved for p-value smaller than
0.05 in the replication sample. It is evident from (B) how, given a p-value
threshold, miRNA associations replicate at a higher rate in independent
samples than just any SNPs or SNPs in intergenic regions. The vertical
intercept is the overall replication rate per category. The cumulative
replication rate mirrors the TDR as should be expected.
Goulart et al. BMC Genomics  (2015) 16:304 Page 8 of 10Unfortunately, we did not have access to sub-studies
from other meta-analyses, but we expect we would
achieve a similar increase in statistical power for other
complex phenotypes as well.
Induction or repression of miRNA expression can sig-
nificantly influence most biological processes, such as
apoptosis, cell fate specification, cell proliferation, DNA
repair, cell cycle and DNA methylation. Associations be-
tween miRNAs and human diseases such as autoimmune
diseases, skin diseases, neurological and psychiatric dis-
eases, cancer, cardiovascular diseases, asthma and others
have repeatedly confirmed the important biological role
played by miRNA [39-43].
Disease-associated SNPs can affect miRNA in many
ways e.g. altering its processing, maturation and expres-
sion. SNPs in both miRNAs and miRNA targets can then
affect their interaction and binding affinity [17]. Indeed, it
has been experimentally validated that 52% of SNPs in thedbSNP database would be able to create novel miRNA
binding sites [44].
The first GWAS finding that was explained by poly-
morphic miRNA targeting was the synonymous SNP
(c.313C > T) in the 3′UTR of IRGM (immunity-related
GTPase family M protein) [45].This SNP decreases the
binding of mir-196 and is associated with the risk of
Crohn's disease. Another SNP, rs1625579, located in the
intron of a putative primary transcript for the mir-137
gene, has been associated with schizophrenia [19], This
SNP alters the seed sequence of miR-137 that is involved
in neuronal development. Four other genes associated
with schizophrenia (TCF4 (transcription factor 4), CAC-
NA1C (calcium channel, voltage-dependent, L type, alpha
1C subunit), CSMD1 (CUB and Sushi multiple domains 1)
and C10orf26 (chromosome 10 open reading frame 26)
contain predicted target-binding sites for miR-137, what
indicates that the expression levels of these genes could
also be affected by the mechanisms described above
[17,19]).
The same miRNA can bind to several different
mRNAs, and each mRNA can be bound by different
miRNAs, thus their overall effect can be enhanced. Our
study is not without limitations and these are largely due
to weaknesses of the current miRNA target prediction
Goulart et al. BMC Genomics  (2015) 16:304 Page 9 of 10methods. The mRNA targets of miRNAs can be
predicted by bioinformatic algorithms such as PicTar,
miRanda and TargetScan [46-48]. However, the predic-
tion of the functional consequences of coding changes
remains a challenge, since the majority of the data are
derived from microarray analysis, with limitations of
miRNA expression profile of the microarray chip. Rele-
vant techniques such as deep sequencing, custom SNP
arrays, as well as target capture methods and functional
prediction efforts in complex traits (target-prediction
algorithms) are rapidly emerging, bringing new hopes of
better understanding to be achieved. Examining miRNAs
profiles in tissues cells could further elucidate their
involvement in complex pathologies. Since expression of
miRNAs is influenced by environmental factors, the
miRNA enrichment could help separating environmental
and genetic factors involved in the development of
disorders.
Conclusions
In conclusion, the current findings demonstrate the
enrichment of microRNA-related SNPs in a variety of
GWASs of complex human phenotypes. Such enrich-
ment can be used to improve the detection of signifi-
cant associations and thus open new ways to further
investigate mechanistic relationships between miRNAs
and complex disorders.
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